Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells by Terauchi, Mikio et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Inhibition of APN/CD13 leads to suppressed progressive potential 
in ovarian carcinoma cells
Mikio Terauchi, Hiroaki Kajiyama*, Kiyosumi Shibata, Kazuhiko Ino, 
Akihiro Nawa, Shigehiko Mizutani and Fumitaka Kikkawa
Address: Department of Obstetrics and Gynecology, Nagoya University, Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya 466-
8550, Japan
Email: Mikio Terauchi - mikio727@med.nagoya-u.ac.jp; Hiroaki Kajiyama* - kajiyama@med.nagoya-u.ac.jp; 
Kiyosumi Shibata - shiba@med.nagoya-u.ac.jp; Kazuhiko Ino - kazuino@med.nagoya-u.ac.jp; Akihiro Nawa - nawa2005@med.nagoya-u.ac.jp; 
Shigehiko Mizutani - shigehiko-m@proof.ocn.ne.jp; Fumitaka Kikkawa - kikkawaf@med.nagoya-u.ac.jp
* Corresponding author    
Abstract
Background: Aminopeptidase N (APN/CD13), a 150-kDa metalloprotease, is a multifunctional
cell surface aminopeptidase with ubiquitous expression. Recent studies have suggested that APN/
CD13 plays an important role in tumor progression of several human malignancies. In the current
study, we investigated the role of APN/CD13 in ovarian carcinoma (OVCA) progression.
Methods: We first examined the expression of APN/CD13 at the protein level in a variety of
OVCA cell lines and tissues. We subsequently investigated whether there was a correlation
between APN/CD13 expression and invasive potential of various OVCA cell lines. Moreover, we
investigated the function of APN/CD13 in OVCA cells using bestatin, an APN/CD13 inhibitor, or
transfection of siRNA for APN/CD13.
Results: We confirmed that APN/CD13 was expressed in OVCA tissues and cell lines to various
extents. There was a positive correlation between APN/CD13 expression and migratory potential
in various OVCA cell lines with accordingly enhanced secretion of endogenous MMP-2.
Subsequently, we found a significant decrease in the proliferative and migratory abilities of OVCA
cells after the addition of bestatin or the inhibition of APN/CD13 expression by siRNA.
Furthermore, in an animal model, daily intraperitoneal administration of bestatin after inoculation
of OVCA cells resulted in a decrease of peritoneal dissemination and in prolonged survival of nude
mice.
Conclusion:  The current data indicate the possible involvement of APN/CD13 in the
development of OVCA, and suggest that clinical use of bestatin may contribute to better prognosis
for ovarian carcinoma patients.
Background
Aminopeptidase N (APN/EC 3.4.11.2) is a type II mem-
brane-bound metalloproteinase expressed on various cell
types, such as kidney, intestinal epithelium, liver, pla-
centa, and lung cells [1-3]. APN is also a cell surface ami-
nopeptidase that was originally characterized as a myeloid
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marker[4]. APN/CD13 activates or inactivates bioactive
peptides on the cell surface by cleaving them enzymati-
cally and regulates their availability to adjacent cells.
Importantly, recent reports have indicated that APN/
CD13 has a variety of functions, including roles in inflam-
matory and immunological responses, signal transduc-
tion, antigen processing, neuropeptide and cytokine
degradation, and extracellular matrix degradation [5-9].
In addition, a number of studies have provided evidence
that APN/CD13 may play a role in tumor progression by
regulating processes such as cell-cell contact, prolifera-
tion, tumor invasion, and angiogenesis [5,10-14]. Fur-
thermore, a recent study showed that APN/CD13 was
involved in the protection of leukemic cells against apop-
tosis[15].
Epithelial ovarian carcinoma (OVCA) is a major cause of
death among gynecological malignancies [16]. Since
OVCA frequently remains clinically silent, the majority of
patients with this disease have advanced intraperitoneal
metastatic disease at diagnosis [17]. The biological behav-
ior of this carcinoma is associated with clinicopathologi-
cal parameters, including International Federation of
Gynecologists and Obstetricians (FIGO) stage, tumor
grade, and histological type. Treatment for advanced
OVCA is difficult because of both the inability to com-
pletely resect diffuse tumors on the peritoneal surface and
the eventual resistance of the tumor cells to chemother-
apy.
We have investigated the molecular mechanism of OVCA
progression. Especially, our recent reports focused on the
involvement of cell surface aminopeptidases such as
dipeptidyl peptidase IV (DPPIV/CD26) and neutral
endopeptidase 24.11 (NEP/CD10) in the peritoneal pro-
gression of this carcinoma, and demonstrated that overex-
pression of DPPIV or NEP in highly invasive OVCA cells
significantly decreased peritoneal dissemination and
increased survival time in a mouse model [18,19].
In the current study, we investigated the possible role of
APN/CD13 in OVCA progression. We first examined the
expression level of APN/CD13 in various OVCA cell lines.
Subsequently, to clarify the cellular roles of APN/CD13 in
OVCA, we investigated the progression of OVCA in vitro
and in vivo using bestatin, an APN/CD13 inhibitor, or
siRNA specific for APN/CD13. The possible function of
this enzyme as an inducer of OVCA progression is pro-
posed.
Methods
Cell culture
Seven human OVCA cell lines (SKOV-3, HRA, ES-2, HEY,
NOS2, NOS4, and TAOV) were cultured and maintained
as described previously [19]. ES-2 and HEY cells were pur-
chased from the American Type Culture Collection
(ATCC) and were maintained in RPMI-1640 (Sigma) sup-
plemented with 10% fetal calf serum (FCS) and penicil-
lin-streptomycin. These cells were incubated at 37°C in a
humidified atmosphere containing 5% CO2.
Enzyme activity assay
APN/CD13 enzyme activity was measured spectrophoto-
metrically using L-leucine-p-nitroanilide (Peptide Insti-
tute, Inc.) as an APN/CD13 substrate. Whole-cell
suspensions were prepared in test tubes, and then washed
with phosphate-buffered saline (PBS). Thereafter, 5 × 105
cells were resuspended in 200 μl of PBS in each well of a
96-well microtiter plate, and the substrate was added
(final 1.6 mM). APN/CD13 enzyme activity was estimated
by measuring the absorbance at 405 nm using a micro-
plate reader (Labsystems, Multiskan Bichromatic) every
15 min during incubation at 37°C.
Flow cytometric analysis
Fluorescence-activated cell sorting (FACS) was performed
to quantify the expression level of APN/CD13 on the cell
surface of OVCA cells. Then, the cells were incubated with
phycoerythrin-conjugated monoclonal antibody specific
for APN/CD13 (BD Pharmingen, CD13mAb clone:
WM15, San Diego, CA) for 30 min at 4°C, and washed
three times with PBS. FACS data were acquired on a FACS
Calibur (Becton Dickinson, San Jose, CA), and analyzed
using CELL Quest software (Becton Dickinson).
Immunohistochemical staining
Fourteen tissue samples of OVCA were obtained with
informed consent from patients who were surgically
treated at Nagoya University Hospital. All samples were
fixed in 10 percent formalin and embedded in paraffin,
and sections were cut at a thickness of 4 μm. For heat-
induced epitope retrieval, deparaffinized sections in 0.01
M citrate buffer were treated three times for 5 min at 90°C
at 750 W using a microwave oven. Immunohistochemical
staining was performed using the avidin-biotin immu-
noperoxidase technique (Histofine SAB-PO kit, Nichirei,
Tokyo, Japan). Endogenous peroxidase activity was
blocked by incubation with 3% H2O2, and non-specific
immunoglobulin binding was blocked by incubation
with 10% normal rabbit serum. As a first antibody for
APN/CD13 staining, anti-APN/CD13 mAb (Novocastra,
CD13mAb clone: 38C12, Newcastle, United Kingdom)
was used at a dilution of 1:100.
Inhibition of APN/CD13 by small interfering RNA
We designed and purchased two different siRNA duplexes
of APN/CD13, si-CD13 (sense, 5'-CACCUUGGACCAAA-
GUAAA-3'), and si-CD13-2 (sense, 5'-
GAAAUGCCACACUGGUCAA-3') from Qiagen (Tokyo,
Japan). Nonspecific control siRNA duplexes (si-cont)BMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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(sense, 5'-CUGGAUUGUAGGAAGUACCTT-3') with the
same GC content as APN/CD13 siRNA were purchased
from Takara (Tokyo, Japan). The siRNA was transfected
into ES-2 cells at a final concentration of 80 nmon/L using
a GenePorter-2 (Genlantis, San Diego, CA) according to
the manufacturer's protocol.
Cell doubling time
Cells growing in log phase were harvested and plated in a
6-well plate at 7.5 × 104 cells/well in RPMI1640 +10%
FCS. The number of cells was counted at 24, 48, 72, and
96 h. The cell doubling time in log phase was determined
in three separate experiments.
Cytotoxicity assay: trypan blue dye-exclusion test
The trypan blue dye-exclusion test was used to determine
drug-mediated cytotoxicity as described previously[20].
The following preparations were assessed for their ability
to inhibit cell growth. Briefly, target tumor cells were
resuspended in medium at 25 × 104 cells/mL after verify-
ing cell viability by the trypan blue dye exclusion test
(Sigma Chemical Co.). First, cells were incubated for 24 h
at 25 × 104 cells/well using 6-well, flat-bottomed plates.
Then, various concentrations of drug samples were added
for a further 24 h. Each plate was incubated for 72 h at
37°C in a 5% CO2 atmosphere. Following the incuba-
tions, 100 μL of the trypan blue dye was added to 100 μL
of cell suspension, and viable and dead cells were
counted. To estimate the cytotoxicity, control cell groups
without any drug treatment were compared with drug-
treated cell groups, and the experiments were repeated
three times.
Cell proliferation assay
The cell proliferation assay was performed as described
previously [18]. Cells were seeded in triplicate in 96-well
plates at a density of 2000 cells in a volume of 200 μl of
RPMI1640 containing 10% FCS, and cultured for 1 to 4
days in the presence or absence of bestatin (Nihon-Kay-
aku, Tokyo, Japan). Cell viability was assayed by a modi-
fied tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay using a Cell Titer 96
Aqueous One Solution Cell Proliferation Assay kit
(Promega Corp., Tokyo, Japan) according to the manufac-
turer's instructions. Absorbance was measured at 492 nm
using a microplate reader (Multiskan Bichromatic; Labsys-
tems Helsinki, Finland). Furthermore, we examined the
effect of siRNA transfection on the proliferation of ES-2
cells. ES-2 cells were seeded in 96-well plates at 1500 cells/
well in 200 μl of culture medium containing 10% FCS.
After 24 hours, the medium was replaced by fresh RPMI
1640 containing 5% FCS and transfection of the siRNA
duplexes (si-cont and si-CD13) was performed in same
the 96-well plate using a GenePorter-2 (Genlantis, San
Diego, CA). Cell proliferation was then evaluated using a
5-day modified MTT assay as described above.
In vitro migration assay
Cell migration was assayed in 24-well Transwell cell cul-
ture chambers (Costar). Cells were suspended in the
upper chamber at a final concentration of 50 × 104/ml in
200 μl of RPMI 1640 in the presence or absence of besta-
tin (0, 10, 100, or 200 μg/ml). The lower chamber con-
tained 700 μl of RPMI 1640 supplemented with 10% FCS.
After 8 hour of incubation, the tumor cells remaining on
the upper surface of the filters were removed by wiping
with cotton swabs, and the migrated cells on the lower
surface were stained with May-Grünwald Giemsa staining.
The number of cells on the lower surface of the filters was
counted under a microscope at a magnification of 200. In
addition, we examined the effect of siRNA transfection on
the migration of ES-2 cells. ES-2 cells were seeded in 10-
cm dishes in RPMI1640 containing 10% FCS. After reach-
ing 50% confluency, the medium was replaced by fresh
RPMI 1640 containing 10% FCS, and transfection of
siRNA (si-cont or si-CD13) was performed using a GeneP-
orter-2 (San Diego, CA). Sixty hours after transfection, the
cells were trypsinized and pelleted. Subsequently, the cells
were re-plated in the upper chambers of Transwell plates
at a density of 50 × 104/ml in 200 μl of RPMI 1640. The
lower chamber contained 700 μl of RPMI 1640 supple-
mented with 10% FCS. The subsequent procedures were
the same as described above. We performed four individ-
ual experiments in which this assay was performed in trip-
licate.
MMP-2 and VEGF quantification by ELISA
OVCA cells were seeded into 6-well culture dishes, and
incubated in culture medium. After achieving subconflu-
ency, cells were washed with RPMI1640 containing 1%
FCS, and incubated for 48 hours. After incubation, the
culture supernatants were tested using MMP-2 ELISA kits
(R&D Systems, Minneapolis, MN) according to the man-
ufacturer's protocol. Experiments were performed in trip-
licate. In addition, we examined the effect of siRNA
transfection on MMP-2 and VEGF expression in ES-2 cells.
ES-2 cells were seeded in 6-well dishes in RPMI1640 con-
taining 10% FCS. After the cells reached 50% confluency,
the medium was replaced by fresh RPMI 1640 containing
10% FCS, and transfection of siRNA (si-cont or si-CD13)
was performed using a GenePorter-2 (Genlatis, San
Diego, CA). Twenty-four hours after transfection, the
medium was replaced by fresh RPMI1640 containing 1%
FCS. After 48 hours of incubation, the culture superna-
tants were collected. The subsequent procedures were the
same as described above using MMP-2 and VEGF ELISA
kits (R&D Systems, Minneapolis, MN).BMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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In vivo studies
Five-week-old female nude mice (BALB/c) were provided
by Japan SLC (Nagoya, Japan). The treatment protocol
followed the guidelines for animal experimentation
adopted by Nagoya University. HRA or SKOV-3 cells (5 ×
106 cells/0.5 ml of medium/mouse) were injected i.p. to
examine their peritoneal metastatic potential. The survival
time was examined with or without treatment with besta-
tin.
Intraperitoneal (i.p.) administration of bestatin (20 mg/
kg body weight) was initiated 24 hours after tumor inoc-
ulation, and was continued daily for 28 days (n = 7). In
the control group (n = 7), vehicle only was administered
in the same manner. Survival time was compared between
these two groups. To confirm same results, this experi-
ment was repeated twice.
Statistical analysis
For data of in vitro and vivo experiments, statistical com-
parisons among groups were performed by the Student's
t-test or ANOVA with Bonferroni corrections. Data are
expressed as mean ± SD. P < 0.05 was considered signifi-
cant.
Results
APN/CD13 expression in OVCA tissues and cell lines
We first examined APN/CD13 expression in 14 surgically
resected OVCA samples. APN/CD13 was predominantly
expressed in tumor cells of OVCA tissues, although the
intensity of immunohistochemical staining varied from
tumor to tumor. (Fig. 1A-D). However, in some tumors,
APN/CD13 was also expressed in stromal cells (Fig. 1E).
The clinicopathological data of the OVCA tissues exam-
ined are summarized in Table 1. In addition, we found a
small number of APN/CD13-positive blood vessels in all
OVCA tissues although the vascular density did not seem
to be associated with the APN/CD13 expression in the
tumor cells. Fig. 2 shows the varying levels of APN/CD13
expression in OVCA cell lines, as measured by FACS anal-
ysis. SKOV-3, ES-2 and HEY cells were intensely positive
for APN/CD13, while in other cell lines, the level of APN/
CD13 expression was lower, which was consistent with
data obtained by enzyme activity analysis (data not
shown).
Correlation among APN/CD13 expression, migratory 
potential, MMP-2 expression and cell doubling time
Table 2 shows the correlation among mean fluorescence
intensity of APN/CD13 in FACS, migratory potential,
MMP-2 expression, and cell doubling time in these OVCA
cell lines. The APN/CD13 expression in these cell lines
was positively correlated with their migratory potential
and with MMP-2 expression. In contrast, there was no
obvious correlation between the expressions of APN/
CD13 and doubling time among these OVCA cell lines. In
addition, the morphology of APN/CD13-expressing cell
lines tended to show a long spindle/bipolar pattern
resembling fibroblasts, in contrast to that of non-APN/
CD13-expressing cell lines, which show an epithelioid
pattern.
The effect of bestatin on proliferation and migration of 
APN/CD13-expressing OVCA cells in vitro
To investigate the function of APN/CD13 in OVCA cells,
we used bestatin, an APN/CD13 inhibitor, in ES-2 cells,
which expressed considerable amounts of APN/CD13. We
confirmed that the APN/CD13 activity of ES-2 cells was
markedly reduced by bestatin, as demonstrated by
reduced absorbance in the enzymatic activity assay (p <
0.001) (Fig. 3A). Fig. 3C shows that more than 100 μg/ml
of bestatin significantly inhibited the proliferation of ES-
2 cells. However, bestatin did not influence the prolifera-
tion of HRA cells, which expressed a low level of APN/
CD13 (Fig. 3D). We performed the trypan blue dye-exclu-
sion test to evaluate the cytotoxity of the bestatin concen-
tration used. We confirmed that there was no obvious
cytotoxic effect of bestatin on HRA cells but that bestatin
dose-dependently induced cytotoxicity in ES-2 cells (Fig.
3B).
We also assessed the effect of bestatin on migration in
OVCA cells. As shown in Fig. 4, the addition of bestatin
significantly inhibited the migration of ES-2 and SKOV-3
cells in the Transwell migration assay in a concentration-
dependent manner. In contrast, bestatin did not influence
the migration of HRA cells (data not shown).
Effect of inhibition of APN/CD13 using siRNA on the 
migration and proliferation of ES-2 cells
To further confirm the significance of APN/CD13 expres-
sion in the cellular function of OVCA, we examined the
effect of APN/CD13 silencing using an siRNA system in
ES-2 cells. Two siRNAs (si-CD13 and si-CD13-2) that spe-
cifically reduced the APN/CD13 protein level were devel-
oped. Since the si-CD13 was more efficient for the
reduction of APN/CD13 expression compared with si-
CD13-2 (data not shown), we used si-CD13 in the follow-
ing experiment. Fig. 5A shows Western blot analysis of
APN/CD13 expression at 24, 48, and 72 hours post trans-
fection. The APN/CD13 protein level was most efficiently
reduced after 72 hours of transfection. At this point, the
migratory potential of si-CD13-transfected cells as esti-
mated using the Transwell migration assay was signifi-
cantly reduced to approximately 30% of that of the si-
cont-transfected cells (Fig. 5B). Based on our finding that
the migratory potential was downregulated by the silenc-
ing of APN/CD13 using siRNA, we next directly examined
the effect of APN/CD13 inhibition on the MMP-2 and
VEGF expression. The MMP-2 and VEGF expression in theBMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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APN/CD13 expression in OVCA tissues A, B, C, D and E; Immunohistological staining of APN/CD13 in surgically resected  OVCA tissues of 14 patients representing four different histological types using APN/CD13 specific Ab Figure 1
APN/CD13 expression in OVCA tissues A, B, C, D and E; Immunohistological staining of APN/CD13 in surgically resected 
OVCA tissues of 14 patients representing four different histological types using APN/CD13 specific Ab. A-D; APN/CD13 was 
expressed intensely in tumor cells but only slightly in stromal cells. A; clear cell carcinoma (case 7), B; endometrioid adenocar-
cinoma (case 8), C; mucinous cystadenocarcinoma (case 5), D; serous cystadenocarcinoma (case 12), E; serous cystadenocarci-
noma (case 2), APN/CD13 was intensely expressed in stromal cells but was almost undetectable in tumor cells. F; APN/CD13-
negative control of serous cystadenocarcinoma. Black arrows indicate tumor cells expressing APN/CD13; green arrows indi-
cate stromal cells expressing APN/CD13.
AB C
D EF
Table 1: Summary of patient characteristics and APN/CD13 expression
Case PT Histological type Tumor grade APN/CD13 (tumor 
expresion)
1 1c endometrioid 1 N
23 c s e r o u s 2N
3 3c mucinous 2 P
43 c s e r o u s 3N
5 1a mucinous 1 P
6 3c mucinous 1 N
7 1c clear cell N.D. P
8 2c endometrioid 2 P
9 1c clear cell N.D. P
10 2c serous 3 P
11 1c clear cell N.D. N
12 3c serous 2 P
13 1c endometrioid 1 N
14 1a mucinous 1 N
N.D.: Not determined, N: Negative, P: PositiveBMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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APN/CD13 expression in various OVCA cell lines, as estimated by FACS analysis A; ES-2 cells, B; HEY cells, C; SKOV-3 cells, D;  TAOV cells, E; NOS-4 cells, F; NOS-2 cells and G; HRA cells Figure 2
APN/CD13 expression in various OVCA cell lines, as estimated by FACS analysis A; ES-2 cells, B; HEY cells, C; SKOV-3 cells, D; 
TAOV cells, E; NOS-4 cells, F; NOS-2 cells and G; HRA cells.
AB C
D E F G
Table 2: Correlation among APN/CD13 expression, migratory potential, and MMP-2 activity in OVCA cell lines
APN/CD13a 
expression
Migratoryb cell 
counts
MMP-2c activity Doubling time (h) Morphology
ES-2 987.3 168 ± 22 34.2 ± 4.8 18.6 ± 3.7 Fibroblastic
HEY 692.6 153 ± 19 31.5 ± 5.1 22.3 ± 2.4 Fibroblastic
SKOV-3 65.2 125 ± 23 23.9 ± 3.9 18.6 ± 4.7 Fibroblastic
HRA 4.5 129 ± 7 1.9 ± 0.9 17.4 ± 2.6 Fibroblastic
TAOV 7.4 22 ± 8 3.2 ± 2.1 20.2 ± 3.2 Epithelioid
NOS2 5.0 11 ± 4 1.6 ± 1.2 18.9 ± 3.7 Epithelioid
NOS4 3.8 17 ± 6 1.7 ± 0.9 19.4 ± 3.1 Epithelioid
a Mean fluorescence intensity by FACS analysis
b By Transwell migration assay × 200 HPF
c By ELISA assay in conditioned medium (ng/ml)BMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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conditioned medium of si-CD13-transfected ES-2 cells
was 20.7% and 71.1% lower than that in si-cont-trans-
fected cells, as shown in Figure 6A and 6B, respectively.
Furthermore, silencing of APN/CD13 by siRNA resulted
in a reduction of the growth rate of ES-2 cells (Fig. 7). The
si-cont-transfected cells proliferated at the same rate as the
parental ES-2 cells. In contrast, si-CD13-transfected cells
could not grow at all.
The effect of bestatin on the peritoneal progression of 
ovarian carcinoma cells in a nude mice model
Finally, we tested whether bestatin influenced the perito-
neal dissemination or survival of OVCA using nude mice.
We previously confirmed that carcinomatous peritonitis
was observed approximately 2 or 4 weeks after the inocu-
lation of HRA or SKOV-3 cells, respectively, in mice. In the
current experiments, daily intraperitoneal administration
of bestatin after tumor inoculation was performed. The
results showed that in the SKOV-3 cell-inoculated group,
treatment with bestatin resulted in decreased peritoneal
dissemination and prolonged survival of the mice. On the
other hand, in the HRA cell-inoculated group, bestatin did
not influence peritoneal dissemination or survival (Fig. 8
and Table 3).
Discussion
Cell-surface peptidases play a key role in controlling the
growth, differentiation and signal transduction of many
cellular systems by modulating the activity of peptide fac-
tors and regulating their access to receptors [4]. According
Differential effects of bestatin on cell proliferation of ES-2 and HRA cells Figure 3
Differential effects of bestatin on cell proliferation of ES-2 and HRA cells. A; Decrease of APN/CD13 enzyme activity by besta-
tin in a concentration-dependent manner in ES-2 cells, which expressed APN/CD13. More than 100 μg/ml of bestatin signifi-
cantly inhibited APN/CD13 enzyme activity in ES-2 cells (p < 0.01). B; Cytotoxicity of bestatin was evaluated by trypan blue 
dye-exclusion test for APN/CD13-positive ES-2 cells and APN/CD13-negative HRA cells. C; Bestatin dose-dependently sup-
pressed cell proliferation of ES-2 cells, which strongly expressed APN/CD13. More than 100 μg/ml of bestatin significantly 
inhibited the proliferation of ES-2 cells (p < 0.01). D; Bestatin exerted no significant effect on the proliferation of HRA cells, 
which expressed a low level of APN/CD13.
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to several other reports, APN/CD13 is involved in the
enhanced cell motility and invasive ability of tumor cells,
and in the neovascularization of endothelial cells [5,21-
23]. In the current study, we focused on the expression
and function of APN/CD13 in OVCA. We showed that the
morphology of APN/CD13-expressing cell lines tended to
show a spindle/bipolar fibroblast-like pattern, which was
associated with high invasiveness and enhanced MMP-2
expression. In contrast, cells with low expression of APN/
CD13 showed an epithelioid pattern. This effect of APN/
CD13 on morphology was opposite the effect of DPPIV/
CD26 on OVCA cells shown in our previous report [24].
Based on this result, although APN/CD13 and DPPIV/
CD26 are both cell surface aminopeptidases, their effects
on migratory potential and cell morphology are thought
to be opposite. Kehlen et al. reported that undifferentiated
anaplastic thyroid carcinomas expressed larger amounts
of APN/CD13 than differentiated thyroid carcinomas,
whereas in contrast, higher levels of DPPIV/CD26 were
expressed in follicular and papillary thyroid carcinomas
than in undifferentiated anaplastic thyroid carcinomas
[23]. Thus, consistent with our results in OVCA, the
expression patterns of DPPIV/CD26 and APN/CD13 in
thyroid carcinoma were also opposite. Our present data
demonstrated that the invasiveness and/or migratory
potential are comparatively strong in CD13+/CD26-
OVCA cells (e.g., ES-2, SKOV-3, and HEY cells); in con-
trast, these abilities are weak in CD13-/CD26+ OVCA cells
(e.g., TAOV, NOS2, and NOS4 cells). We think that there
may be a crosstalk between APN/CD13 and DPPIV/CD26
expressions in a variety of cells, and that the expression-
balance between these two molecules may be critical for
the cellular invasive potential, although further studies are
needed to confirm this. However, HRA cells are CD13-/
CD26-type, and thus their characteristics cannot be
explained by the CD13/CD26 balance, and their invasive-
ness must be based on some other mechanism.
To study the function of APN/CD13 in OVCA, we first
used bestatin (Ubenimex), which is a competitive inhibi-
Bestatin inhibited the cell motility of APN/CD13-expressing OVCA cells in the Transwell migration assay in a concentration- dependent manner Figure 4
Bestatin inhibited the cell motility of APN/CD13-expressing OVCA cells in the Transwell migration assay in a concentration-
dependent manner. A: SKOV-3 cells; *; p < 0.01, **; p < 0.001, B; ES-2 cells; *; p < 0.001, **; p < 0.0001.
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Table 3: The effect of Bestatin on survival time of nude mice
Cells Control-group Bestatin-group
HRA 13.8 ± 0.8 15.8 ± 2.5
SKOV-3 29.0 ± 3.0 *36.1 ± 6.5 (days)
Mean survival days of PBS alone or bestatin treated mice with innoculation of 1.0 × 107 HRA and SKOV-3 cells, respectively. Data are expressed as 
the mean ± SD. *; p < 0.05BMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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tor of APN/CD13 and an antibiotic with inhibitory activ-
ity toward some but not all aminopeptidases [25]. Our
current findings demonstrated that the suppression of
APN/CD13 activity by bestatin in APN/CD13-expressing
cells reduced the migratory and proliferative potential as
well as the peritoneal dissemination in a mice model,
which led to prolonged survival. On the other hand, in
OVCA cells with limited expression of APN/CD13, besta-
tin had no apparent influence on these cell functions
related to tumor progression. These results indicated the
direct involvement of APN/CD13 in the tumor-progres-
sion of OVCA, which was consistent with the finding of
previous reports. Considering these results, APN/CD13
activity may play a crucial role in cell motility and the
metastasis of OVCA, since APN/CD13 has been suggested
to be involved in the degradation of neuropeptides,
cytokines, and immunomodulatory peptides, as well as
angiotensins [26,27]. Riemann et al. reported that in
leukemic cells, APN/CD13 expression may contribute to
the malignant phenotype via proteolytically modifying
peptides and/or their precursors involved in growth stim-
ulation or retardation [6]. Although bestatin affects the
enzymatic activity of APN/CD13, it is not necessarily spe-
cific for APN/CD13 and bestatin can directly cause apop-
tosis in tumor cells besides its ability to inhibit APN/
CD13 activity. Therefore, an siRNA method able to down-
regulate all functions of APN/CD13 was used in our cur-
rent in vitro examination. The results showed that silenc-
ing of APN/CD13 expression by siRNA induced a marked
decrease in the migratory and proliferative potential of
OVCA cells with a concurrent down-regulation of MMP-2
and VEGF expression. Chan et al. provided strong evi-
Suppression of APN/CD13 expression by siRNA induced a marked decrease in migratory potential of ES-2 cells Figure 5
Suppression of APN/CD13 expression by siRNA induced a marked decrease in migratory potential of ES-2 cells. A; Western 
blot analysis showed a decrease in APN/CD13 expression after siRNA transfection. B, C; Giemsa staining showing the migra-
tion of ES-2 cells transfected with non-specific control siRNA (B; si-cont) or siRNA specific for APN/CD13 (C; si-CD13), 
respectively. D; The level of migration of ES-2 cells transfected with si-CD13 relative to the control was 33%. Data are 
expressed as the mean ± SD *; p < 0.01.
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dence that APN/CD13 activity was not absolutely
required for enhanced migration by demonstrating that
expression of a catalytically inactive form of APN/CD13
significantly enhanced the migration of lung adenocarci-
noma cells [27]. Taken together, our results also support
the notion that APN/CD13 may promote cancer cell
migration or metastasis by both aminopeptidase-depend-
ent and aminopeptidase-independent mechanisms.
With regard to the effect of APN/CD13 expression on the
progression of OVCA, van Hensbergen et al, previously
reported that there was no distinct effect of APN/CD13-
overexpression on the growth of OVCA cells (IGROV-1
cells) in vitro, but it was associated with decreased inva-
sive ability[28]. In our current study, inhibition of APN/
CD13 by siRNA resulted in a reduction of the growth and
invasion of OVCA cells, although there was no obvious
correlation between the expression of APN/CD13 and
doubling time of various OVCA cells. Unfortunately, we
can not explain for this discrepancy at present. However,
our assay was based on the inhibition of APN/CD13
expression or its activity using siRNA or bestatin, which
was somewhat different from their assays using APN/
CD13-overexpressing transfectants. In addition, the dis-
crepancy may be due to some peculiarity of IGROV-1
cells, because the work of Hensbergen et al, was derived
from the results using this single cell line. Also, the dis-
crepancy might be due to differences of the expression of
several unknown co-factors that facilitate the function of
APN/CD13. At any rate, to elucidate the mechanistic func-
tion of APN/CD13 including these discrepancies, further
investigations of APN/CD13 in tumor biology will be
essential.
Clinically, several reports have shown that APN/CD13
was correlated with poor prognosis in several malignan-
cies [9,29]. Hashida et al. reported that APN/CD13 was
involved in cell motility or angiogenesis, and that the
expression of this enzyme was associated with poor prog-
nosis for node-positive patients with human colon cancer
[9]. According to the recent report from Surowiak et al.
[30], there was a slight, although not significant, prognos-
tic difference between patients positive for APN/CD13
expression and those negative for APN/CD13 expression.
However, in their study, the majority of the cases were at
stage-III (95%). We think that this could have caused
some bias. Namely, in many survival analyses including
several clinicopathological factors, stage is an independ-
ent prognostic factor. If the influence of stage was very
strong, the importance of APN/CD13 expression as a
prognostic factor might become weak. Thus, a larger
Inhibition of proliferative potential by the transfection of  siRNA for APN/CD13 in ES-2 cells in a 4-day modified MTT  assay Figure 7
Inhibition of proliferative potential by the transfection of 
siRNA for APN/CD13 in ES-2 cells in a 4-day modified MTT 
assay. Analysis of the proliferation rate was performed as 
described in "MATERIALS AND METHODS". si-CD13-trans-
fected cells showed almost no growth, whereas the si-cont-
transfected cells grew similarly to the parental ES-2 cells. 
Closed circles; si-cont-transfected cells, gray squares; si-CD13-
transfected cells. Data are expressed as the mean ± SD of 
four independent experiments. *; p < 0.01, **; p < 0.001.
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Decrease of MMP-2 and VEGF expression caused by RNA  interference of APN/CD13 in ES-2 cells using MMP-2 and  VEGF ELISA kit Figure 6
Decrease of MMP-2 and VEGF expression caused by RNA 
interference of APN/CD13 in ES-2 cells using MMP-2 and 
VEGF ELISA kit. The MMP-2 and VEGD expression in the 
conditioned medium of si-CD13-transfected ES-2 cells was 
significantly lower than that of si-cont-transfected cells. Data 
are expressed as the mean ± SD, A; *p < 0.001, B; *p < 0.05.BMC Cancer 2007, 7:140 http://www.biomedcentral.com/1471-2407/7/140
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number of patients including early stage (I-II) have to be
examined in the next analysis of the prognosis of OVCA.
Considering the body of evidence about APN/CD13,
including our current results, APN/CD13 may be a target
for treatment of OVCA. If effective, bestatin may be one of
the candidate drugs with APN/CD13 as a clinical target,
and is already being used clinically for the treatment of
leukemia. According to a recent report by Ichinose et al.,
survival was significantly better for patients with com-
pletely resected stage I squamous-cell lung carcinoma
who were treated with bestatin as a postoperative adju-
vant therapy than for those who received a placebo [31].
Conclusion
The data obtained in the current investigation demon-
strated the expression APN/CD13 in OVCA associated
with tumor cell motility, proliferation and metastasis.
Therefore, further insights into the mechanism and func-
tion of APN/CD13 in tumor biology may be critical, as
APN/CD13 may constitute a potential therapeutic target
in a variety of malignancies.
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